The search for a balance between short and long-term treatment outcomes in multiple sclerosis

Journal of Neurology

Volumn 255, Issue SUPPL. 1, 2008, Pages 75-83

  Baumhackl, Ulf ^a  

^a Landesklinikum ^*  (Austria)

Author keywords

Beta interferon; Disease progression; Glatiramer acetate; Multiple sclerosis; Treatment

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; PLACEBO;

CLINICAL TRIAL; CONFERENCE PAPER; DISABILITY; DISEASE COURSE; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOMODULATION; LONG TERM CARE; MEDICAL INFORMATION; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PATIENT EDUCATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; DISEASE PROGRESSION; HUMANS; MULTIPLE SCLEROSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 40349100001     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-008-1010-8     Document Type: Conference Paper

References (30)

1. Bornstein MB, Miller A, Slagle S, Weitzman M, Crystal H, Drexler E, Keilson M, Merriam A, Wassertheil-Smoller S, Spada V, et al. (1987) A pilot trial of Cop 1 in exacerbatingremitting multiple sclerosis. N Engl J Med 317:408-414
2. Comi G, Filippi M, Wolinsky JS (2001) European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging - measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 49:290-297
3. Compston A, Coles A (2002) Multiple sclerosis. Lancet 359:1221-1231
4. Confavreux C, Vukusic S, Moreau T, Adeleine P (2000) Relapses and progression of disability in multiple sclerosis. N Engl J Med 343:1430-1438
5. Food and Drugs Administration (1995) Avonex; Summary Basis for Approval. In: US Food and Drugs Administration
6. Ford C, Johnson K, Brooks B, Goodman A, Kachuck N, Lisak R, Myers L, Panitch H, Pruitt A, Rizzo M, Rose J, Wolinsky J (2003) Sustained efficacy and tolerability of glatiramer acetate in relapsing-remitting multiple sclerosis patients for over 10 years. Mult Scler 9(Suppl 1):S120
7. Ford CC, Johnson KP, Lisak RP, Panitch HS, Shifronis G, Wolinsky JS (2006) A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler (Houndmills, Basingstoke, England) 12:309-320
8. Gonsette RE (2004) A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis. Exp Opin Pharmacother 5:747-765
9. Haas J (2005) Open-label study to compare the clinical efficacy of immunomodulatory therapies (glatiramer acetate and interferons) in relapsing-remitting multiple sclerosis: four years of follow up. J Neurol 252(Suppl 2):108
10. Haas J, Firzlaff M (2005) Twentyfour-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone). Eur J Neurol 12:425-431
11. rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH, et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39:285-294
12. ®) in patients with relapsing remitting multiple sclerosis (RRMS). Mult Scler 8(Suppl.1):S7-S8
13. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45:1268-1276
14. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS (1998) Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 50:701-708
15. Johnson KP, Brooks BR, Ford CC, Goodman A, Guarnaccia J, Lisak RP, Myers LW, Panitch HS, Pruitt A, Rose JW, Kachuck N, Wolinsky JS (2000) Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler (Houndmills, Basingstoke, England) 6:255-266
16. Johnson KP, Brooks BR, Ford CC, Goodman AD, Lisak RP, Myers LW, Pruitt AA, Rizzo MA, Rose JW, Weiner LP, Wolinsky JS (2003) Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. Mult Scler (Houndmills, Basingstoke, England) 9:585-591
17. Johnson KP, Ford CC, Lisak RP, Wolinsky JS (2005) Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. Acta Neurol Scand 111:42-47
18. Kappos L, Stam Moraga M (2002) Long-term tolerability of interferon beta 1a in relapsing-remitting multiple sclerosis: 6-year safety follow-up of the PRISMS study. Mult Scler 8(Suppl 1):S120
19. Khalili K, White MK, Lublin F, Ferrante P, Berger JR (2007) Reactivation of JC virus and development of PML in patients with multiple sclerosis. Neurology 68:985-990
20. Lassmann H, Bruck W, Lucchinetti C (2001) Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 7:115-121
21. Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:907-911
22. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121-127
23. Multiple Sklerose Therapie Konsensus Gruppe (MSTKG), Rieckmann P (2006) Immunmodulatorische Stufentherapie der Multiplen Sklerose. Der Nervenarzt 77:1506-1518
24. Noseworthy JH, O'Brien P, Erickson BJ, Lee D, Sneve D, Ebers GC, Rice GP, Auty A, Hader WJ, Kirk A, Duquette P, Carter J, Francis G, Metz L, Shuster E (1998) The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis. Neurology 51:1342-1352
25. Pittock SJ, Mayr WT, McClelland RL, Jorgensen NW, Weigand SD, Noseworthy JH, Weinshenker BG, Rodriguez M (2004) Change in MS-related disability in a populationbased cohort: a 10-year follow-up study. Neurology 62:51-59
26. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498-1504
27. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group (2001) PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 56:1628-1636
28. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45:1277-1285
29. Weinshenker BG (1995) The natural history of multiple sclerosis. Neurol Clin 13:119-146
30. Wolinsky JS, Comi G, Filippi M, Ladkani D, Kadosh S, Shifroni G (2002) Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained. Neurology 59:1284-128